Rapport Therapeutics (RAPP) Stock Seems Pricey Following A 29% Monthly Slide

Rapport Therapeutics has seen a sharp pullback recently, and that slump puts fresh focus on whether the current share price ...

Inside the $1 billion blockbuster opportunity sending Rapport Therapeutics stock higher

Positive trial data for Rapport’s lead pipeline candidate, RAP-219, a treatment for bipolar mania, points to a potential $1 ...
Fintel on MSN

Rapport Therapeutics consensus price target increased by 10.79% to $69.65

The average one-year price target for Rapport Therapeutics (NASDAQGM:RAPP) has been revised to $69.65 / share. This is an increase of 10.79% from the prior estimate of $62.87 dated September 29, 2026.

Rapport’s epilepsy drug finds surprising success in bipolar trial

Despite what some analysts described as low expectations, RAP-219 narrowly hit the main goal of a mid-stage study, results ...
Seeking Alpha

Rapport: Surging On Phase 2 Study Win - Full Approval Unlikely Before 2028

Rapport Therapeutics, Inc.'s RAP-219 delivered impressive Phase 2a results in drug-resistant focal onset seizures, driving Rapport Therapeutics' stock up over 135% and boosting investor optimism. The ...
investors

Rapport Stock Doubles After Succeeding In Hard-To-Treat Seizures

Shares of Rapport Therapeutics (RAPP) catapulted on Monday after the biotech company's experimental drug significantly reduced seizures in patients with a hard-to-treat form of epilepsy. The company ...
Kalkine Media

Rapport Therapeutics Director Ramiro Sanchez Acquires 3,600 Shares at $27.35 Each

RAPP (NASDAQ:RAPP) director Ramiro Sanchez acquired 3,600 shares of common stock on October 23, 2026. This purchase, coded "P ...